clinical endpoint raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-18. Anything still debated is marked as such rather than presented as settled.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
Lyophilized thymosin alpha-1 is generally stored at or below minus twenty degrees Celsius, protected from moisture and light. Short-term handling at ambient temperature is possible for dry powder, but reconstituted solutions degrade faster and are usually kept at two to eight degrees Celsius with a defined expiry of days rather than weeks. Repeated freeze-thaw cycles should be avoided because they promote aggregation and loss of potency. Exact limits depend on the formulation and should follow the supplier's documentation.
Identity and purity are normally assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and truncation products. Mass spectrometry confirms molecular mass and detects modifications such as deamidation or oxidation. Amino acid analysis and peptide mapping provide additional sequence-level confirmation. For research material, a certificate of analysis typically reports these results together with water content and counter-ion identity, since the lyophilized powder is often supplied as an acetate or trifluoroacetate salt.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
== Sultanate and Kingdom of Egypt == The Order was established in 1915 by Sultan Hussein Kamel of Egypt for award to persons who had rendered useful service to the country. It ranked beneath the Order of Ismail and was frequently awarded to British officers and officials serving in Egypt, as well as distinguished Egyptian citizens.The order comprised five classes:
Colloidal gold is a sol or colloidal suspension of nanoparticles of gold in a fluid, usually water. The colloid is coloured usually either wine red (for spherical particles less than 100 nm) or blue-purple (for larger spherical particles or nanorods). Due to their optical, electronic, and molecular-recognition properties, gold nanoparticles are the subject of substantial research, with many potential or promised applications in a wide variety of areas, including electron microscopy, electronics, nanotechnology, materials science, and biomedicine. The properties of colloidal gold nanoparticles, and thus their potential applications, depend strongly upon their size and shape. For example, rodlike particles have both a transverse and longitudinal absorption peak, and anisotropy of the shape affects their self-assembly.
April 30: Decree dismissing "useless" women (prostitutes) from armies. June 10–11: Decree on communal property division, allowing women and men over 21 to participate and vote in assemblies. June 24: Constitution of Year I denies women citizenship rights. June 28: Decree on annual aid for children, the elderly, and the indigent, mandating districts to provide secret housing for pregnant girls to give birth, with confidentiality and funded care (children born become wards of the nation); free childbirth care for indigent women, mandatory breastfeeding (except for medical reasons) for indigent families, with financial aid. August 24: Married women's annuities and interest remain theirs but are paid directly to husbands. October 30: Decree banning women's political clubs and societies. December 19: Decree mandating state-organized compulsory primary education for girls and boys aged 6–8. 1794
One of the possible sites of ulnar nerve entrapment is the cubital tunnel which is where Osborne's ligament is located. When Osborne's ligament is present, the volume of the cubital tunnel decreases when the elbow is flexed. This contributes to chronic compression of the ulnar nerve which causes numbness and weakness in the fingers and can lead to intrinsic paralysis of the hand in untreated severe cases. Decompression of the ulnar nerve can be achieved through surgery. Alternatively, in mild cases of the entrapment, non-operative conservative treatment, which includes nerve gliding and wearing a splint at night, may be used to alleviate the nerve compression. A scratch collapse test can be utilized to evaluate the condition as well as pinpoint the location of the nerve entrapment by Osborne's ligament. The test begins with the patient sitting with their elbow flexed at 90° and their fingers pointing toward the examiner. The examiner then rotates the patient's forearm medially or inward towards the patient's torso. The patient is asked to resist the motion, and the examiner gauges the resulting resistance. Following this, the examiner strokes the area on the patient's arm that is thought to be the site of impingement. The examiner then rotates the patient's forearm medially again. If there is a noticeable reduction in the resistance, the test's result is considered positive, and the stroked area is likely confirmed to be the site of the nerve entrapment.
Amit Agrawal, Chief Scientific Officer, Diagnostics Platform, Danaher Ava Amini, Principal Researcher, Microsoft Warren Chan, Dean of the College of Engineering and President's Chair Professor in Engineering, Nanyang Technological University Singapore Arnav Chhabra, Co-founder, Satellite Bio Alice Chen, Chief Operating Officer, Curve Biosciences Amanda Chen, Vice President, Vertex Ventures HC Tal Danino, Associate Professor, Columbia University Jaideep Dudani, CEO, Ouro Medicines Gabe Kwong, Professor, Georgia Institute of Technology Geoffrey von Maltzahn, General Partner at Flagship Pioneering Vyas Ramanan, Venture Partner, Third Rock Ventures Simone Schürle-Finke, Associate Professor, ETH Zurich Andrew Warren, Senior Director, Curie.Bio
Sources: en.wikipedia.org
freeway removal incentives, heavy-duty alternative fuel vehicle grants, grants for training contractors to perform home electrifications, grants for environmental justice promotion, grants for improvements to state and local environmental impact assessment capacity, and the EPA's green bank, the Greenhouse Gas Reduction Fund.
TikTok tends to appeal to younger users, as 41% of its users are between the ages of 16 and 24. As of 2021, these individuals are considered Generation Z. TikTok's geographical use in 2019 has shown that 43% of new users were from India before the social platform was banned in the country. But adults have also seen growth on TikTok. The share of US adults who regularly get news from TikTok hit 5% in 2025. By July 2023, TikTok has become the primary news source for British teenagers on social media, with 28% of 12 to 15-year-olds relying on the platform, while traditional sources like BBC One/Two are more trusted at 82%, according to a report by UK regulator Ofcom. As of the first quarter of 2022, there were over 100 million monthly active users in the United States and 23 million in the UK. The average user, daily, was spending 1 hour and 25 minutes on the app and opening TikTok 17 times. Out of TikTok's top 100 male creators, a 2022 analysis reported 67% were white, with 54% having near-perfect facial symmetry.
=== Category:EC 2.8 (transfer sulfur-containing groups) === EC 2.8.1.1: Thiosulfate sulfurtransferase EC 2.8.1.2: 3-mercaptopyruvate sulfurtransferase EC 2.8.1.3: Thiosulfate—thiol sulfurtransferase EC 2.8.1.4: tRNA uracil 4-sulfurtransferase EC 2.8.1.5: Thiosulfate—dithiol sulfurtransferase EC 2.8.1.6: Biotin synthase EC 2.8.1.7: Cysteine desulfurase EC 2.8.1.8: Lipoyl synthase EC 2.8.1.9: Molybdenum cofactor sulfurtransferase EC 2.8.1.10: Thiazole synthase EC 2.8.1.11: Molybdopterin synthase sulfurtransferase EC 2.8.1.12: Molybdopterin synthase EC 2.8.1.13: tRNA-uridine 2-sulfurtransferase EC 2.8.1.14: tRNA-5-taurinomethyluridine 2-sulfurtransferase EC 2.8.1.15: tRNA-5-methyluridine(54) 2-sulfurtransferase
== Digestion == Most proteins are decomposed to single amino acids by digestion in the gastro-intestinal tract. Digestion typically begins in the stomach when pepsinogen is converted to pepsin by the action of hydrochloric acid, and continued by trypsin and chymotrypsin in the small intestine. Before the absorption in the small intestine, most proteins are already reduced to single amino acid or peptides of several amino acids. Most peptides longer than four amino acids are not absorbed. Absorption into the intestinal absorptive cells is not the end. There, most of the peptides are broken into single amino acids. Absorption of the amino acids and their derivatives into which dietary protein is degraded is done by the gastrointestinal tract. The absorption rates of individual amino acids are highly dependent on the protein source; for example, the digestibilities of many amino acids in humans, the difference between soy and milk proteins and between individual milk proteins, beta-lactoglobulin and casein. For milk proteins, about 50% of the ingested protein is absorbed between the stomach and the jejunum and 90% is absorbed by the time the digested food reaches the ileum. Biological value (BV) is a measure of the proportion of absorbed protein from a food which becomes incorporated into the proteins of the organism's body.
Sources: en.wikipedia.org
The program was intended to be leading-edge, and many features of the program which were legal at the time, including Tribulus and intravenous vitamin C, were outlawed by 2014. Most of the supplements were administered away from Essendon's Windy Hill facilities. A total of 38 players consented to the program, although ASADA ultimately pursued cases against only 34 of those players, based on the supporting evidence it found through the investigation. The program of injections began in November 2011. In January 2012, Essendon's club doctor, Dr Bruce Reid, raised concerns about aspects of the program to the club. In particular, Dank had not liaised with Reid on the details of the program, which included administering substances that Reid had not personally approved, which was against the historical chain of accountability within the club. Reid wrote a letter to Hird and club general manager Paul Hamilton in January, recording his opinion that the substances Dank was administering were "playing at the edge" of legality with the potential to "read extremely badly in the press for [the] club", and that he was unconvinced that either the benefits or the side effects were well understood. At that point, the club's administrators agreed that Reid's approval was required in the future; however, evidence gathered during the investigation indicated Reid was largely kept out of the loop from that point on.
=== Gene therapy === Gene therapy is a therapeutic approach that involves modifying or replacing faulty genes to treat or prevent diseases. In theranostics, gene therapy can be combined with diagnostic imaging to monitor the delivery, expression, and activity of therapeutic genes. Imaging techniques such as MRI, PET, and optical imaging enable non-invasive assessment of gene transfer and expression, providing valuable insights into the efficacy and safety of gene-based treatments. Gene therapy has shown potential in treating genetic disorders, cancer, and cardiovascular diseases, and its integration with diagnostic imaging offers a comprehensive approach for monitoring and optimizing treatment outcomes.
Stop bleeding – to help to seal the wound to expedite the clotting process; Protection from infection – to defend the wound against germs and mechanical damage; Absorb exudate – to soak up blood, plasma, and other fluids exuded from the wound, containing it/them in one place and preventing maceration; Ease pain – either by a medicated analgesic effect, compression or simply preventing pain from further trauma; Debride the wound – to remove slough and foreign objects from the wound to expedite healing; Reduce psychological stress – to obscure a healing wound from the view of the patient and others. Ultimately, the aim of a dressing is to promote healing of the wound by providing a sterile, breathable and moist environment that facilitates granulation and epithelialization. This will then reduce the risk of infection, help the wound heal more quickly, and reduce scarring. Applying, or changing a dressing is a first aid skill, although many people undertake the practice with no training – especially on minor wounds. Modern dressings will almost all come in a prepackaged sterile wrapping, date coded to ensure sterility. Historically, in emergencies and in many less developed regions, dressings are often improvised using available materials such as clothing or spare fabric. These makeshift dressings can serve basic functions like stemming bleeding and absorbing exudate, though, such improvised dressings often need to be used in combination with antiseptic solutions like povidone-iodine to reduce the chances of infection.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.